{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:57:57Z","timestamp":1793059077850,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clindermatol.2026.09.037","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:15:07Z","timestamp":1790896507000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-like peptide-1 receptor agonists in psoriasis management"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7855-8319","authenticated-orcid":false,"given":"Marley","family":"Cutrona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Talia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5759-9796","authenticated-orcid":false,"given":"Ahuva","family":"Cices","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2026.09.037_bib0001","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0002","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0003","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2026.102148","article-title":"Global epidemiology of psoriatic arthritis","volume":"40","author":"Kalyoncu","year":"2026","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.clindermatol.2026.09.037_bib0005","article-title":"National prevalence of psoriatic arthritis in the United States: data from National Health and Nutrition Examination Survey [NHANES]","volume":"76","author":"Poudel","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0006","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0007","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0008","article-title":"Psoriasis and obesity: optimizing pharmacologic treatment and lifestyle interventions","volume":"24","author":"Guo","year":"2025","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0009","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/1203475415586332","article-title":"The relationship of obesity with the severity of psoriasis: a systematic review","volume":"19","author":"Fleming","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0010","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0011","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamadermatol.2026.0859","article-title":"The National Psoriasis Foundation Primer on GLP-1 receptor agonists in psoriasis: a review","volume":"162","author":"Sheth","year":"2026","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0012","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaad.2012.08.015","article-title":"Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies","volume":"68","author":"Armstrong","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0013","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/exd.13467","article-title":"Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities","volume":"27","author":"Krueger","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0014","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41584-025-01326-6","article-title":"The obesity-inflammation axis in psoriatic disease: mechanisms and therapeutic strategies","volume":"22","author":"Haberman","year":"2026","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0016","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/art.70134","article-title":"Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial","volume":"78","author":"Merola","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0017","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdin.2026.04.004","article-title":"Efficacy of glucagon-like peptide 1 analogues in psoriasis: a cohort study","volume":"26","author":"Bar","year":"2026","journal-title":"JAAD Int"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0018","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ced\/llaf473","article-title":"Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study","volume":"51","author":"Nicolau","year":"2026","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.medcli.2025.106941","article-title":"Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control?","volume":"164","author":"Nicolau","year":"2025","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0020","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.medcli.2023.05.021","article-title":"Effects of liraglutide among patients living with psoriasis and obesity","volume":"161","author":"Nicolau","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0021","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study","volume":"150","author":"Xu","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0022","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","article-title":"Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study","volume":"27","author":"Ahern","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0023","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study","volume":"171","author":"Buysschaert","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0024","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamadermatol.2026.1753","article-title":"Ixekizumab with or without tirzepatide in adults with psoriasis and overweight or obesity: a phase 3b randomized clinical trial","volume":"162","author":"Lebwohl","year":"2026","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/biom15010046","article-title":"Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial","volume":"15","author":"Petkovi\u0107-Dabi\u0107","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0026","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial","volume":"33","author":"Lin","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0027","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdv.12629","article-title":"Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients: a randomized placebo-controlled trial","volume":"29","author":"Faurschou","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0028","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40257-026-01049-8","article-title":"A systematic review of the clinical impact of GLP-1 receptor agonists in hidradenitis suppurativa","volume":"27","author":"Visan","year":"2026","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.037_bib0029","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.jid.2025.08.045","article-title":"GLP-1 receptor agonists as emerging modulators of inflammation and angiogenesis in chronic cutaneous wound healing","volume":"145","author":"Ghebrehiwet-Kuflom","year":"2025","journal-title":"J Invest Dermatol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:52:05Z","timestamp":1792720325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X26002853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"alternative-id":["S0738081X26002853"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.09.037","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists in psoriasis management","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}